ClassID:

20894

A61K38/046 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof Tachykinins, e.g. eledoisins, substance P; Related peptides

Recent Application in this class:
#1
20250387470
2025-12-25

SKIN MICROENVIRONMENT TARGETED DELIVERY FOR PROMOTING IMMUNE AND OTHER RESPONSES

#2
20240148862
2024-05-09

SKIN MICROENVIRONMENT TARGETED DELIVERY FOR PROMOTING IMMUNE AND OTHER RESPONSES

#3
20240010669
2024-01-11

Compound with analgesic effect for use in prevention and treatment of pain

#4
20230248799
2023-08-10

COMBINATION THERAPY OF SUBSTANCE-P FOR MOBILIZATION OF HEMATOPOIETIC STEM CELLS

#5
20200054620
2020-02-20

Use of Non-Peptidic NK1 Receptor Antagonists for the Production of Apoptosis in Tumour Cells

#6
20190389898
2019-12-26

Compound with analgesic effect for use in prevention and treatment of pain

#7
20190343979
2019-11-14

PREFABRICATED ALGINATE-DRUG BANDAGES

#8
20190201229
2019-07-04

Noxipoints stimulating devices using light, mechanical force, or heat as a source of stimulation

#9
20190083455
2019-03-21

METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS

#10
20190015471
2019-01-17

NK3 agonist for use in the treatment of a patient suffering from atrial arrhythmia or fibrillation

#11
20190000966
2019-01-03

Skin microenvironment targeted delivery for promoting immune and other responses

#12
20180333513
2018-11-22

Prefabricated alginate-drug bandages

#13
20180161388
2018-06-14

SUBSTANCE P, MAST CELL DEGRANULATION INHIBITORS, AND PERIPHERAL NEUROPATHY

#14
20180140658
2018-05-24

Method of treating a wound, comprising the step of administering a composition including a substance P

#15
20180117027
2018-05-03

USE OF NON-PEPTIDIC NK1 RECEPTOR ANTAGONISTS FOR THE PRODUCTION OF APOPTOSIS IN TUMOUR CELLS

#16
20180042984
2018-02-15

Pharmaceutical composition for preventing or treating arthritis

#17
20170065663
2017-03-09

SUBSTANCE AND METHOD FOR TREATING INFLUENZA

#18
20160361378
2016-12-15

Bifunctional compounds for relief of pain comprising an opioid receptor agonist moiety and a NK1 receptor antagonist moiety and methods for treating pain

#19
20160058903
2016-03-03

Prefabricated alginate-drug bandages

#20
20160032394
2016-02-04

Method for reversing recent-onset type 1 diabetes (T1D) by administering substance P (sP)

#21
20140065109
2014-03-06

Methods of administration of Substance P for wound healing

#22
20120225028
2012-09-06

COMPOSITIONS AND METHODS FOR MOBILIZATION OF STEM CELLS

#23
20120142596
2012-06-07

AGENT FOR STIMULATING MOBILIZATION OF ENDOTHELIAL PROGENITOR CELLS

#24
20120064532
2012-03-15

Use of Serum Amyloid A Gene in Diagnosis and Treatment of Glaucoma and Identification of Anti-Glaucoma Agents

#25
20110256089
2011-10-20

Hydrogel Type Cell Delivery Vehicle for Wound Healing, and Preparation Method Thereof

#26
20110009334
2011-01-13

System and method for inhibiting cellular proliferation with tachykinins

#27
20110008278
2011-01-13

MODULATORS OF PARAPTOSIS AND RELATED METHODS

#28
20100267616
2010-10-21

ACUTE RESPIRATORY SYNDROMES

#29
20100204129
2010-08-12

USE OF A PEPTIDE AS A THERAPEUTIC AGENT

#30
20100184819
2010-07-22

METHOD FOR REDUCING INTRACRANIAL PRESSURE

#31
20100173852
2010-07-08

USE OF AGENTS THAT DOWN-REGULATE EXPRESSION OF TANIS AND/OR P21 Waf1/Cip1/Sd1 GENES, AND USE OF AGENTS THAT INHIBIT, DEGRADE, SEQUESTER OR PREVENT THE NEUROTOXICITY OF GENE PRODUCT PROTEINS OF TANIS AND P21 Waf1/Cip1/Sd1 GENES

#32
20100098671
2010-04-22

COMPOSITION FOR PREVENTION OR TREATMENT OF BONE MARROW DAMAGE

#33
20100092561
2010-04-15

Methods of using substance P to promote healing of vascular wounds

#34
20100062986
2010-03-11

METHOD TO TREAT BLOOD CELL DEPLETION

#35
20090312255
2009-12-17

STIMULATION OF TRPV1+ SENSORY NEURONS TO CONTROL BETA-CELL STRESS AND ISLET INFLAMMATION IN DIABETES

#36
20090298741
2009-12-03

Trophic factor combinations for nervous system treatment

#37
20090286744
2009-11-19

Treatment of asthma

#38
20090221511
2009-09-03

TRPV1 + SENSORY NEURONS CONTROL OF BETA-CELL STRESS AND ISLET INFLAMMATION IN DIABETES

#39
20090203614
2009-08-13

USE OF AGENTS THAT PREVENT THE GENERATION OF AMYLOID-LIKE PROTEINS AND/OR DRUSEN, AND/OR USE OF AGENTS THAT PROMOTE SEQUESTRATION AND/OR DEGRADATION OF, AND/OR PREVENT THE NEUROTOXIC EFFECTS OF SUCH PROTEINS IN THE TREATMENT OF MACULAR DEGENERATION

#40
20090181893
2009-07-16

USE OF AGENTS THAT PREVENT GENERATION OF AMYLOID AND AMYLOID-LIKE LIPOPROTEINS, AND/OR USE OF AGENTS THAT PROMOTE SEQUESTRATION AND/OR DEGRADATION OF, AND/OR PREVENT NEUROTOXICITY OF SUCH PROTEINS IN THE TREATMENT OF HEARING LOSS AND IMPROVING BODY BALANCE

#41
20090137492
2009-05-28

METHOD TO REDUCE THE RISK AND/OR SEVERITY OF ANTHRAX INFECTION

#42
20090105154
2009-04-23

Method for inhibiting or treating intestinal damage caused by radiotherapy or chemotherapy comprising administering substance-P

#43
20090099092
2009-04-16

METHODS FOR STIMULATING FIBROBLAST PROLIFERATION USING SUBSTANCE P ANALOGS

#44
20090075903
2009-03-19

Method of using substance P analogs for treatment amelioration of myelodysplastic syndrome

#45
20090041745
2009-02-12

MODULATORS OF PARAPTOSIS AND RELATED METHODS

#46
20090036371
2009-02-05

Use of Serum Amyloid A Gene in Diagnosis and Treatment of Glaucoma and Identification of Anti-Glaucoma Agents

#47
20090028908
2009-01-29

METHODS FOR TREATING NEUROGENIC INFLAMMATION

#48
20090017071
2009-01-15

METHODS FOR TREATING NEUROGENIC INFLAMMATION

#49
20090012086
2009-01-08

Use of non-peptidic NK1 receptor antagonists for the production of apoptosis in tumour cells

#50
20080318869
2008-12-25

Method to Promote Wound Healing

#51
20080194487
2008-08-14

Treatment of Skin Diseases

#52
20080145386
2008-06-19

TRPV1 sensory neurons control of β-cells stress and islet inflammation in diabetes

#53
20070259378
2007-11-08

Method for identifying agonists or antagonists of the G-protein coupled receptor mas-like 1

#54
20070238661
2007-10-11

Substance P treatment for hepatitis C

#55
20070207209
2007-09-06

Trophic factor combinations for nervous system treatment

#56
20070207123
2007-09-06

Amelioration of effects of cigarette smoke

#57
20070155667
2007-07-05

Acute respiratory syndromes

#58
20070154448
2007-07-05

Methods and compositions using Substance P to promote wound healing

#59
20060281670
2006-12-14

Compositions and methods for modulating angiogenesis

#60
20060247156
2006-11-02

Use of neuropeptides for traumatic cartilage injury

#61
20060204471
2006-09-14

Compositions and regime/regimen for treating the adverse signs of cutaneous skin aging

#62
20060194738
2006-08-31

Cytomodulating peptides for treating interstitial cystitis

#63
20060153789
2006-07-13

Stimulation of hair regrowth

#64
20060127373
2006-06-15

Use of substance P for mobilization of Mesenchymal stem cells or proliferation of Mesenchymal stem cells and for wound healing or facilitating wound healing

#65
20060121039
2006-06-08

Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration

#66
20060078571
2006-04-13

Methods for treating inflammation pain

#67
20060030942
2006-02-09

Use of neuropeptides for ligament healing

#68
20060029678
2006-02-09

Process for the production of implants

#69
20060025344
2006-02-02

Ghrelin receptor inverse agonists for regulation of feeding behaviors

#70
20050267280
2005-12-01

Lactone bearing absorbable polymers

#71
20050244894
2005-11-03

Modulators of paraptosis and related methods

#72
20050197289
2005-09-08

System and method for inhibiting cellular proliferation with tachykinins

#73
20050153927
2005-07-14

Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents

#74
20050137123
2005-06-23

Method for treating glaucoma comprising administering α-lipoic acid

#75
20050137122
2005-06-23

Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance

#76
20050063931
2005-03-24

Hair-follicle treatment,in particular against hair loss